Clinical Rheumatology

, Volume 14, Issue 5, pp 537–543 | Cite as

The clinical and immunological effects of cyclosporin A on patients with rheumatoid arthritis

  • D. M. Chang
  • S. F. Chiao


Ten patients with rheumatoid arthritis entered this open study to investigate the clinical and immunological effects of cyclosporin-A (CsA) on rheumatoid arthritis. A dosage of 2.5mg/kg/day was used, and each patient was examined every two weeks. The clinical assessment was performed on the basis of the number of painful and swollen joints, the duration of morning stiffness, and the physician and patient global assessment. The laboratory assessment included blood and urine analysis, liver and renal function, C-reactive protein (CRP), and erythrocyte sedimentation rate. The cell surface markers were determined by flow cytometer. Soluble interleukin-2 (IL-2) receptor and IL-2 production were determined by ELISA. Eight patients continued through the six-month study, and marked improvement was found after three months in all clinical indices except morning stiffness. The laboratory assessment demonstrated significant decrease of CRP af-ter six months treatment. Serum creatinine, though within normal limit, was about 30% above the baseline value. There was no significant change of IL-2R and HLADR expression on T cells during the therapeutic course. However, statistically significant decreases of both IL-2 production from lymphocytes and serum IL-2R concentration were found after 22 weeks treatment. The current studies suggest that CsA is clinically effective in the treatment of rheumatoid arthritis and may act through suppression of T cells.

Key words

Cyclosporin A Rheumatoid Arthritis Interleukin-2 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yocum, D.E., Klippel, J.H., Wilder, R.L., Gerber, N.L., Austin, H.A., Wahl, S.M., Lesko, L., Minor, J.R., Preuss, H.G., Yarboro, C., Berkebile, C., Dougherty, S.: Cyclosporin A in severe, treatment-refractory rheumatoid arthritis: a randomized study. Ann Intern Med 1988, 109, 863–869.Google Scholar
  2. 2.
    Van Joost, T.H., Bos, J.D., Heule, F., Meinardi, MMHM. Low dose cyclosporin A in severse psoriasis. A double-blind study. Br J Dermatol 1988, 118, 183–90.Google Scholar
  3. 3.
    Bianchi Porro, G., Panza, E., Petrillo, M. Cyclosporin A in acute ulcerative colitis. Ital J Gastroenterol 1987, 9, 40–1.Google Scholar
  4. 4.
    Peltekian, K.M., Williams, C.N., macDonald, A.S., Roy, P., Czolpinska, E. Open trial of cyclosporin in patients with severe active Crohn's disease refractory to conventional therapy. Can J Gastroenterol 1988, 2, 5–11.Google Scholar
  5. 5.
    Shevach, E.M. The effects of cyclosporin A on the immune system. Annu Rev Immunol 1985, 3, 397–423.Google Scholar
  6. 6.
    Reems, G.H., Cook, L.A., Palladino, M.A. Cyclosporin A inhibitits interleukin-2 and gamma interferon synthesis by human thymocytes. Transplant Proc 1983, 15, 2287–9.Google Scholar
  7. 7.
    Granelli-Piperno, A., Andrus, L., Steinman, R.M. Lymphokine and non-lymphokine mRNA levels in stimulated TR cells. Kinetics, mitogen requirements, and effect of cyclosporin A. J Exp Med 1986, 163, 922–937.Google Scholar
  8. 8.
    Kronke, M., Leonard, W.J., Depper, J.M. Cyclosporin A inhibits T cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984, 81, 5214–8.Google Scholar
  9. 9.
    Foxwell, B., Simon, J., Herrero, J., Taylor, D., Woerly, G., Ryffel, B. Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A. Immunology 1990; 69: 104–9.Google Scholar
  10. 10.
    Weinblatt, M.E., Coblyn, J.S., Fraser, P.A., Anderson, R.J., Spragg, J., Trentham, D.E., Austen, K.F.: Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum 1987, 30, 11–17.Google Scholar
  11. 11.
    Dougados, M., Awada, H., Amor, B.: Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1988, 47, 127–133.Google Scholar
  12. 12.
    Tugwell, P., Bombardier, C., Gent, M., Bennett, K.J., Bensen, W.G., Carette, S., Chalmers, A., Esdaile, J.M., Klinkhoff, A.V., Kraag, G.R., Ludwin, D., Roberts, R.S.: Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990, 335, 1051–1055.Google Scholar
  13. 13.
    Dougados, M., Duchesne, L., Awada, H., Amor, B. Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis. Ann Rheum Dis 1989, 48, 50–6.Google Scholar
  14. 14.
    Arnett, F.C., Edworthy, S.M., Bloch, D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31, 315–24.Google Scholar
  15. 15.
    Stenbrocker, O., Traeger, C.H., Batterman, R.C.: Therapeutic criteria in rheumatoid arthritis. JAMA 1949, 140, 659–62.Google Scholar
  16. 16.
    Dougados, M., Amor, B. Cyclosporin A in rheumatoid arthritis: Preliminary clinical results of an open trial. Arthritis Rheum 1987, 30, 83–6.Google Scholar
  17. 17.
    Bowles, C.A., Gabriel, S., Bunch, T.W., et al. Cyclosporin A (CsA) treatment for rheumatoid arthritis (RA). Arthritis Rheum 1987, 30, S58.Google Scholar
  18. 18.
    van Rijthoven, A.W.A.M., Dijkmans, B.A.C., Goei The, H.S., et al: Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicenter study. Ann Rheum Dis 1986, 45, 726–31.Google Scholar
  19. 19.
    Forre, O., Bjerkhoel, F., Salvesen, C.F. et al.: An open controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis. A preliminary report. Arthritis Rheum 1987, 30, 88–92.Google Scholar
  20. 20.
    Weinblatt, M.E., Coblyn, J.S., Fraser, P.A., et al: Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum 1987, 30, 11–7.Google Scholar
  21. 21.
    Tugwell, P., Bombardier, C., Gent, M., et al: Low dose cyclosporine in rheumatoid arthritis: a pilot study. J Rheumatol 1987, 14, 1108–14.Google Scholar
  22. 22.
    Berg, K.J., Forre, O., Bjerkhoel, F., et al: Side effects of cyclosporine A treatment in patients with rheumatoid arthritis. Kidney Int 1986, 29, 1180–7.Google Scholar
  23. 23.
    Dijkmans, B.A.C., van Rijthoven, A.W.A.M., Goei The, H.S., Montnor-Beckers, Z.L.B.M., Jacobs, P.C.J., Cats, A.: Effects of cyclosporine on serum creatinine in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1987, 31, 541–5.Google Scholar
  24. 24.
    Amor, B., Dougados, M. Cyclosporin A in rheumatoid arthritis. Eur J Rheumatol Inflamm 1991, 11, 162–71.Google Scholar
  25. 25.
    Hannedouche, T.P., Delgado, A.G., Gnionsahe, A.D., Boitard, C., Noel, L.H., Grunffeld, J.P. Nephrotoxicity of cyclosporine in autoimmune disease. Adv Nephrol 1990, 19, 169–86.Google Scholar
  26. 26.
    Kahan, B.D. Drug therapy: cyclosporine. N Engl J med 1989, 321, 1725–38.Google Scholar
  27. 27.
    Ludwin, D., Bennett, K.J., Grace, E. et al. Nephrotoxicity in patients with rheumatoid arthritis (RA) treated with cyclosporine. Transplant Proc 1988, 20, 367–70.Google Scholar
  28. 28.
    Tegzess, A.M., Doorenbos, B.M., Minderhoud, J.M., Donker, A.J.M. Prospective serial renal function studies in patients with nonrenal disease treated with cyclosporin A. Transplant Proc 1988, 20(suppl 3), 530–3.Google Scholar
  29. 29.
    Berg, K.J., Forre, O., Djoseland, O., Mikkelsen, M., Narverud, J., Rugstad, H.E. Renal side effects of high and low cyclosporine A doses in patients with rheumatoid arthritis. Clin Nephrol 1989, 31, 232–8.Google Scholar
  30. 30.
    Boers, M., Dijkmans, B.A.C., van, Rijthoven, A.W., Goei The, H.S., Cats, A. Reversible nephrotoxicity of cyclosporine in rheumatoid arthritis. J Rheumatol 1990, 17, 38–42.Google Scholar
  31. 31.
    Tilney, N.L., Whitely, W.D., Diamond, J.R., Kupiec-Weglinski, J.W., Adams, D.H. Chronic rejection-an undefined conundrum. Transplantation 1991, 52, 389–98.Google Scholar
  32. 32.
    Sund, S., Forre, O., Berg, K.J., Kvien, T., Hovig, T. Morphological and functional renal effects of long-term low dose cyclosporine A treatment in patients with rheumatoid arthritis. Clin Nephrol 1992, 34, 168–79.Google Scholar
  33. 33.
    Schroeder, T.J., Brunson, M.E., Perce, A.J., Hindenlang, L.L., Mauser, P.A., Ruckrigl, D.I., Weibel, M.L., Wadih, G., and First, M.R. A comparison of the clinical utility of the radioimmunoassay, high-performance liquid chromatography, and TDx cyclosporine assays in outpatients renal transplant recipients. Transplantation 1989, 47, 262–72.Google Scholar
  34. 34.
    Thompson, S.G.: In Kaplan LA, Pesce, AJ, eds. Clinical Chemistry Theory, Analysis, and Correlation St Louis, MO. Mosby, 1989, 191.Google Scholar
  35. 35.
    Van Buren, D., Wideman, C.A., Reid, M. et al. The antagonistic effect of rifampin upon cyclosporine bioavailability. Transplant Proc 1984, 16, 1642–5.Google Scholar
  36. 36.
    Mauren, G., Lemaire, M. Biotransformation and distribution in blood of cyclosporine and its metabolities. Transplant Proc 1986, 18, 25–34.Google Scholar
  37. 37.
    Malone, D.G., Wahl, S.M., Tsokos, M., et al. Immune function in severe, active rheumatoid arthritis: A relationship between peripheral blood mononuclear cell proliferation to soluble antigens and synovial tissue immunohistologic characteristics. J Clin Invest 1984, 74, 1173–85.Google Scholar
  38. 38.
    Pitzalis, C., Kingsley, G.H., Lanchbury, J.S.S., Murphy, J., Panayi, G.S. Expression of HLA-DR, DQ, DP antigens and interleukin 2 receptor on synovial fluid T lymphocyte subsets in rheumatoid arthritis: Evidence for frustrated rheumatoid arthritis. J Rheumatol 1987, 14, 660–6.Google Scholar
  39. 39.
    Panayi, G.S. The immunopathogenesis of rheumatoid arthritis. British J Rheumatol 1993, 32(1), 4–14.Google Scholar
  40. 40.
    Hess, A.D., Tutschka, P.J., Santos, G.W., Effect of cyclosporin A on human lymphocyte response in vitro. III. CsA inhibits the production of T lymphocytes growth factors in secondary mixed lymphocyte responses but does not inhibit the response of primed lymphocytes to TCGF. J Immunol 1982, 128, 355–9.Google Scholar
  41. 41.
    Azogui, O., Gluckman, E., Fradelizi, D. Inhibition of IL-2 production after allogenetic bone marrow transplantation. J Immunol 1983, 131, 1205–8.Google Scholar
  42. 42.
    Yoshimura, N., Kahan, B.D. Pharmacodynmaic assessment of in vivo cyclosporine effect on interleukin 2 production by lymphocytes of kidney transplant recipients. Transplantation 1985, 40, 661–6.Google Scholar
  43. 43.
    Yocum, D.E., Wilder, R.L., Dougherty, S., Klippel, J.M., Pillemer, S., Wahl, S. Immunologic parameters of response in patients with rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1990, 33(9), 1310–6.Google Scholar
  44. 44.
    Granelli-Piperno, A. In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J Exp Med 1988, 168, 1649–58.Google Scholar
  45. 45.
    Symons, J.A., Wood, N.C., DI Giovine, F.S., Duff, G.W., Soluble IL-2 receptor in rheumatoid arthritis: correlation with disease activity and IL-2R and IL-2 inhibition. J Immunol 1988, 14, 2612–8.Google Scholar
  46. 46.
    Michiaki, T., Noriyuki, K., Akihito, M., Masayuki, I., Kunio, S., Makoto, K., Jiro, T.H. Effect of low dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994, 37(4), 551–8.Google Scholar

Copyright information

© Acta Medica Belgica 1995

Authors and Affiliations

  • D. M. Chang
    • 1
  • S. F. Chiao
    • 2
  1. 1.Division of Rheumatology/Immunology/AllergyTri-Service General Hospital, National Defense Medical CenterTaipeiTaiwan, R.O.C.
  2. 2.Department of Clinical PharmacologyTri-Service General Hospital, National Defense Medical CenterTaipeiTaiwan, R.O.C.

Personalised recommendations